Post-earnings recap
Reported
Tue, Feb 4, 2020
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Neurocrine Biosciences reported a strong EPS performance, exceeding expectations by over 31%. The stock reacted positively, rising 2.64%. However, the lack of revenue data and guidance leaves some uncertainty about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.05 | N/A | +31.13% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the earnings beat on EPS. However, they did not provide detailed revenue figures or future guidance.
We are pleased with our EPS performance this quarter.
Our focus remains on delivering value to our stakeholders.